Sign up to save your podcasts
Or
Share "Senator, We Run Ads": Inside Meta's AI Cash Machine
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
"Senator, We Run Ads": Inside Meta's AI Cash Machine
This week on Telltales: Hunt, Jason, and Mike pressure-test Meta’s position as an AI cash machine, walk through the Iran-driven oil setup, and unpack the FDA shake-up and a second consecutive Harrow miss.
The Cashflow Memo
Key Takeaways
* Meta is the most profitable AI application ever built: revenue doubled from ~$110B in 2021 to a $220B run rate today, with current growth still ~30% YoY on a $200B base — AI rebuilt the attribution layer Apple’s ATT broke in 2021.
* Meta’s capex bet is uniquely uncomfortable: on the last call management told analysts they have no idea what ROIC will be on AI infrastructure spend because, unlike Amazon, Microsoft, Google, and Oracle, Meta isn’t renting the servers — it’s defensive spend against what Zuckerberg called an existential paradigm shift.
* Oil setup remains manageable despite the Iran standoff and Strait of Hormuz closure: near-month crude is in the $90s, full-year 2026 futures price in at ~$79, 2027 at ~$73, against a ~2M bbl/day inventory draw absorbable by ~1B bbls of US crude inventory plus China’s reserve.
* Trump administration’s $1.5T defense ask for fiscal 2027 won’t fully land, but the equipment refresh is happening — bigger concern is US public debt >100% of GNP with no clear capital-markets trigger date, only inevitability.
* Harrow/Vevye second consecutive miss: CVS formulary win pulled high-deductible Q1 patients into the $59 Access-for-All program, forcing rebate outflows of $200–$300 per patient back to the PBM — thesis intact but a 5-year payout, not 2–3 years.
Show Notes
[00:18] Iran Standoff & Crude Inventory Math Hunt frames the Strait of Hormuz closure and the inventory math: a 2M bbl/day draw is absorbable against ~1B bbls of US crude inventory plus China’s reserve.
[04:00] Oil Futures Curve & Gasoline Politics Near-month crude in the $90s, 2026 futures price in at ~$79, 2027 at ~$73 — manageable prices, with a path to ~$3.50 gasoline rather than $4.50.
[05:36] Defense Budget & US Deficit Trump’s $1.5T fiscal 2027 ask won’t fully land, but the equipment refresh is happening. The real concern is public debt >100% of GNP and an uncertain capital-markets trigger.
[07:12] Meta Deep Dive: The Attention Machine Why Meta is unlike other Mag-7 stories — Facebook and Instagram as discovery-to-purchase advertising machines, not search-intent platforms.
[13:04] Meta as the Most Profitable AI Application Ever Built ML in ad ranking since 2007, PyTorch’s origin story, and why Meta has been quietly compounding AI dollars longer than any of the LLM darlings.
[16:56] Apple ATT, Revenue Doubling, and the CapEx Question The 2021–2022 flat-revenue year that forced Meta to rebuild attribution with AI — and the open question of ROIC on today’s infrastructure spend.
[23:29] News: Amazon Supply Chain Services, OpenAI Ads, Nvidia, Tesla, TSMC Amazon stands up a UPS/FedEx competitor, OpenAI launches a self-service ad platform aimed at Google, Nvidia’s earnings cadence, and Musk’s Terra Fab ambitions.
[25:49] FDA Shake-Up: Makary Out, Real-Time Reviews In Marty Makary resigns under pressure after the Replimune denial — but the real story is two new real-time review studies with Amgen and AstraZeneca that could compress drug-approval timelines.
[30:26] Harrow Earnings: The PBM Rebate Trap on CVS Formulary Second consecutive miss. Winning CVS formulary placement pulled high-deductible patients into the $59 Access-for-All program, forcing rebate outflows that wiped out Q1 economics. Thesis intact, payout extended.
Subscribe and get the Cash Flow Memo at telltales.us — financials on ~80 companies plus the oil, natural gas, and US deficit exhibits referenced in every episode.
Cashtags
$META $AAPL $AMZN $GOOGL $MSFT $ORCL $NVDA $TSLA $TSM $CVS $LLY $REPL $AMGN $AZN
This post and the information herein are intended for informational purposes only. The views expressed herein are the author’s alone and do not constitute an offer to sell, or a recommendation to purchase, or a solicitation of an offer to buy, any security, nor a recommendation for any investment product or service. While certain information contained herein has been obtained from sources believed to be reliable, neither the author nor any of his employers or their affiliates have independently verified this information, and its accuracy and completeness cannot be guaranteed. Accordingly, no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, timeliness or completeness of this information. The author and all employers and their affiliated persons assume no liability for this information and no obligation to update the information or analysis contained herein in the future.
This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit telltales.substack.com
View all episodes
By by Top Mark Capital
5
66 ratings
This week on Telltales: Hunt, Jason, and Mike pressure-test Meta’s position as an AI cash machine, walk through the Iran-driven oil setup, and unpack the FDA shake-up and a second consecutive Harrow miss.
The Cashflow Memo
Key Takeaways
* Meta is the most profitable AI application ever built: revenue doubled from ~$110B in 2021 to a $220B run rate today, with current growth still ~30% YoY on a $200B base — AI rebuilt the attribution layer Apple’s ATT broke in 2021.
* Meta’s capex bet is uniquely uncomfortable: on the last call management told analysts they have no idea what ROIC will be on AI infrastructure spend because, unlike Amazon, Microsoft, Google, and Oracle, Meta isn’t renting the servers — it’s defensive spend against what Zuckerberg called an existential paradigm shift.
* Oil setup remains manageable despite the Iran standoff and Strait of Hormuz closure: near-month crude is in the $90s, full-year 2026 futures price in at ~$79, 2027 at ~$73, against a ~2M bbl/day inventory draw absorbable by ~1B bbls of US crude inventory plus China’s reserve.
* Trump administration’s $1.5T defense ask for fiscal 2027 won’t fully land, but the equipment refresh is happening — bigger concern is US public debt >100% of GNP with no clear capital-markets trigger date, only inevitability.
* Harrow/Vevye second consecutive miss: CVS formulary win pulled high-deductible Q1 patients into the $59 Access-for-All program, forcing rebate outflows of $200–$300 per patient back to the PBM — thesis intact but a 5-year payout, not 2–3 years.
Show Notes
[00:18] Iran Standoff & Crude Inventory Math Hunt frames the Strait of Hormuz closure and the inventory math: a 2M bbl/day draw is absorbable against ~1B bbls of US crude inventory plus China’s reserve.
[04:00] Oil Futures Curve & Gasoline Politics Near-month crude in the $90s, 2026 futures price in at ~$79, 2027 at ~$73 — manageable prices, with a path to ~$3.50 gasoline rather than $4.50.
[05:36] Defense Budget & US Deficit Trump’s $1.5T fiscal 2027 ask won’t fully land, but the equipment refresh is happening. The real concern is public debt >100% of GNP and an uncertain capital-markets trigger.
[07:12] Meta Deep Dive: The Attention Machine Why Meta is unlike other Mag-7 stories — Facebook and Instagram as discovery-to-purchase advertising machines, not search-intent platforms.
[13:04] Meta as the Most Profitable AI Application Ever Built ML in ad ranking since 2007, PyTorch’s origin story, and why Meta has been quietly compounding AI dollars longer than any of the LLM darlings.
[16:56] Apple ATT, Revenue Doubling, and the CapEx Question The 2021–2022 flat-revenue year that forced Meta to rebuild attribution with AI — and the open question of ROIC on today’s infrastructure spend.
[23:29] News: Amazon Supply Chain Services, OpenAI Ads, Nvidia, Tesla, TSMC Amazon stands up a UPS/FedEx competitor, OpenAI launches a self-service ad platform aimed at Google, Nvidia’s earnings cadence, and Musk’s Terra Fab ambitions.
[25:49] FDA Shake-Up: Makary Out, Real-Time Reviews In Marty Makary resigns under pressure after the Replimune denial — but the real story is two new real-time review studies with Amgen and AstraZeneca that could compress drug-approval timelines.
[30:26] Harrow Earnings: The PBM Rebate Trap on CVS Formulary Second consecutive miss. Winning CVS formulary placement pulled high-deductible patients into the $59 Access-for-All program, forcing rebate outflows that wiped out Q1 economics. Thesis intact, payout extended.
Subscribe and get the Cash Flow Memo at telltales.us — financials on ~80 companies plus the oil, natural gas, and US deficit exhibits referenced in every episode.
Cashtags
$META $AAPL $AMZN $GOOGL $MSFT $ORCL $NVDA $TSLA $TSM $CVS $LLY $REPL $AMGN $AZN
This post and the information herein are intended for informational purposes only. The views expressed herein are the author’s alone and do not constitute an offer to sell, or a recommendation to purchase, or a solicitation of an offer to buy, any security, nor a recommendation for any investment product or service. While certain information contained herein has been obtained from sources believed to be reliable, neither the author nor any of his employers or their affiliates have independently verified this information, and its accuracy and completeness cannot be guaranteed. Accordingly, no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, timeliness or completeness of this information. The author and all employers and their affiliated persons assume no liability for this information and no obligation to update the information or analysis contained herein in the future.
This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit telltales.substack.com